Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration

Morgan Stanley says lithium supply needs to jump 10x in four years. The problem: While there's plenty of lithium, there are no new mines. But, new research reveals a young company with a massive lithium property in the heart of the Lithium Triangle. [ad] You can get your free report here. Hidden Income 'hack' This hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing. [ad] Click here to get this secret The Perfect Time to Buy an IPO One recent IPO is in the perfect buying position. Bloomberg's 2019 "stock picker of the year" picked up 6.5 million shares. And the lead investor behind Google and Amazon put in hundreds of millions. [ad] Here's why RIGHT NOW is the perfect time to get in. While there's plenty of lithium, there are no new mines...Click HERE Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion Myovant MYOV, +32.62% will receive an upfront payment of $650 million to develop and market relugolix, a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which won approval from the U.S. Food and Drug Administration in December as a treatment for advanced prostate cancer. DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.

2563 cherry hill ln, hermitage, PA 16148, United States You may unsubscribe or change your contact details at any time. Powered by: